From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The medication, gepotidacin, targets E. coli bacteria, which is responsible for ...

Guangdong Provincial Key Laboratory of Information Photonics Technology, Guangdong Provincial Key Laboratory of Functional Soft Condensed Matter, School of Material and Energy, Guangdong University of ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Phase 3 trials EAGLE-2 and EAGLE-3 showed gepotidacin's non-inferiority and superiority to nitrofurantoin in treating uUTIs. Gepotidacin achieved higher therapeutic and microbiological success rates ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new antibiotic to treat urinary tract infections (UTIs). The drug gepotidacin, which will be sold under the ...

Study participants were randomly assigned to receive gepotidacin 1500mg twice daily or nitrofurantoin 100mg twice daily for 5 days. The primary endpoint for both trials was the combined clinical ...

Urinary tract infections (UTIs) are among the most common medical issues women experience; up to 60% of women will get one during their lifetime. Older, post-menopausal women are especially ...